Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

First International Summit on Interventional Pharmacoeconomics

Welcome and Introduction to Vi3C

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Amit Sanyal, MD: A Clinician’s Perspective

Nov

Today In Oncology

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Related Videos

Welcome and Introduction to Vi3C

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Amit Sanyal, MD: A Clinician’s Perspective

FDA Approves Durvalumab With FLOT for Resectable Gastric-GEJ Adenocarcinoma

AI Simplifies Patients Comprehension of CT Reports But Are Errors Possible

External Validation Confirms Ability of AI Model to Stratify Recurrence Risk in Early-Stage Lung Cancer

No Overall Survival Benefit for Lenvatinib in LEAP-014 Trial of Esophageal Cancer

ASTRO Publishes First Clinical Guideline on Radiation Therapy for Gastric Cancer